Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Neonatal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Pulse vs continuous dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).

1 finding from 1 review

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
RR 1.38 [1.02, 1.88]
2 studies · 197 participants
Low

Pulse vs continuous dexamethasone therapy

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).

1 finding from 1 review

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
RR 1.23 [0.79, 1.92]
1 study · 76 participants
Very low

Intervention not reported

Threshold · asymptomatic newborns at the time of pulse oximetry screening

The review found no eligible studies for this question.

1 finding from 1 review

Pulse oximetry screening for critical congenital heart defects 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

95% (less than or less than or equal to) · asymptomatic newborns at the time of pulse oximetry screening

1 finding from 1 review

Pulse oximetry screening for critical congenital heart defects 2018 · Cochrane Headline outcomes only
no estimate extracted
19 studies · 436758 participants
Low